On August 11, Everforth (NYSE:EFOR) said its federal segment, Everforth ECS, had won a four-year, $30 million contract to support the Defense Health Agency’s technology modernization program. The deal lands less than two weeks after Everforth’s July 29, second-quarter report showed revenue, net income, and margins all landing above the high end of management’s own guidance. Together, the two events paint a mixed picture: a company picking up fresh federal work even as its top line and profit keep shrinking year over year.
A New Foothold In Defense Health
The DHA award gives Everforth ECS a four-year foothold inside the Defense Health Agency’s Information Technology Program Support and Analytics Services program, the operational backbone for modernizing the Military Health System’s technology portfolio. Everforth ECS will build predictive AI models, executive dashboards, and performance metrics that give DHA leaders visibility into program cost, schedule, cybersecurity risk, and cloud spending. President Donnie Scott called it a way to help military health leaders make faster, more informed decisions, and the scope, spanning AI, cybersecurity and cloud work, matches the practice areas Everforth has built its commercial business around.
That win arrived alongside a second quarter that beat the company’s own targets. Revenue of $1.01 billion and Adjusted EBITDA of $96.7 million both cleared the high end of guidance, and the Federal Government Segment’s gross margin actually improved to 19.6%, up 40 basis points from a year earlier, even as segment revenue slipped. Everforth also used the quarter to strengthen its balance sheet, repurchasing 0.4 million shares for $11.5 million, repaying $23.9 million of debt, and following the quarter’s end by refinancing its revolver into a new five-year, $600 million facility. With roughly $923 million still authorized for buybacks and a Commercial Segment book-to-bill ratio of 1.2 to 1, management has both room to keep returning cash and a demand signal that bookings are outpacing billings on the commercial side.
Growth Slows While Backlog Shrinks
The same report that beat guidance also showed a business still smaller than it was a year ago. Consolidated revenue of $1.01 billion was down from $1.02 billion in the second quarter of 2025, with both the Commercial Segment ($701.7 million versus $708.1 million) and the Federal Government Segment ($305.3 million versus $312.5 million) posting year-over-year declines. Net income fell to $14.2 million, or $0.35 per diluted share, from $29.3 million and $0.67 a year earlier, and Adjusted EBITDA margin compressed to 9.6% from 10.6%. Selling, general and administrative expenses rose to $226.2 million from $216.8 million, partly on $9.8 million of acquisition, integration and strategic planning costs.
The federal segment, the one just celebrating the DHA award, is also the one flagging a backlog problem. Its book-to-bill ratio over the trailing twelve months sits at 0.8 to 1, meaning new awards of $0.9 billion have been running behind what the segment bills out, and the year-over-year revenue decline was tied to weakness in Defense and Intelligence and Federal Civilian work. Total long-term debt climbed to $1,438.1 million at June 30, from $1,169.4 million at the end of 2025, a reminder that the same quarter that funded buybacks and debt paydown also expanded the balance sheet.
Wall Street’s Split Verdict
Hedge fund ownership of Everforth climbed to 21 funds from 15 in the prior quarter, which points to institutions adding to positions rather than trimming them. Short interest sits at 11.87% of the float, a level that signals a real bear camp has built a position against the stock. At the same time, shares trade at a forward P/E of just 7.49, as of September 14, pricing in little of the growth the DHA contract or the commercial bookings pickup might eventually deliver. That combination is not one where the market has settled on a story yet.
Where The Story Goes Next
Everforth now has two competing narratives running at once. One is a federal contractor picking up meaningful new mission-critical work and beating its own financial targets while shoring up its balance sheet. The other is a company whose revenue and profit are still smaller than they were a year ago, with its federal backlog growing more slowly than it is being spent down. For the DHA win and the guidance beat to matter beyond a single quarter, that federal book-to-bill ratio needs to turn higher and commercial revenue needs to stop sliding.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
